Progress Report On UK's Early Access Scheme: A Limited Success But Could Do Better
This article was originally published in SRA
The UK's early access to medicines scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed. Sten Stovall talks to those in the industry that have first-hand experience of the process.
You may also be interested in...
UK proposals to promote innovation and speed access to promising new drugs could among other things prompt new payment models. The final report on the government’s Accelerated Access Review should be out by the end of the month.
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.